Nathan D. Jorgensen Vor Biopharma Inc. (VOR) insider trading activity

Nathan D. Jorgensen is CHIEF FINANCIAL OFFICER of Vor Biopharma Inc.. Currently has a direct ownership of 189,403 shares of VOR, which is worth approximately $164,780. The most recent transaction as insider was on May 06, 2024, when has been sold 834 shares (Common Stock) at a price of $1.75 per share, resulting in proceeds of $1,459. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 189K

0% 3M change

30.04% 12M change

Total Value Held $164,780

Nathan D. Jorgensen Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
May 06 2024	SELL Payment of exercise price or tax liability	$1,459 $1.75 p/Share	834 Reduced 0.44%	189,403 Common Stock
May 01 2024	SELL Payment of exercise price or tax liability	$1,623 $1.77 p/Share	917 Reduced 0.48%	190,237 Common Stock
Mar 01 2024	SELL Payment of exercise price or tax liability	$14,323 $2.27 p/Share	6,310 Reduced 3.2%	191,154 Common Stock
Feb 06 2024	SELL Payment of exercise price or tax liability	$2,285 $2.32 p/Share	985 Reduced 0.5%	197,464 Common Stock
Jan 29 2024	BUY Grant, award, or other acquisition	-	50,000 Added 20.12%	198,449 Common Stock
Nov 06 2023	SELL Payment of exercise price or tax liability	$1,517 $1.82 p/Share	834 Reduced 0.57%	145,647 Common Stock
Sep 01 2023	SELL Payment of exercise price or tax liability	$16,847 $2.67 p/Share	6,310 Reduced 4.13%	146,481 Common Stock
Aug 07 2023	SELL Payment of exercise price or tax liability	$2,226 $2.67 p/Share	834 Reduced 0.54%	152,791 Common Stock
May 08 2023	SELL Payment of exercise price or tax liability	$3,452 $4.14 p/Share	834 Reduced 0.54%	153,625 Common Stock
Mar 01 2023	SELL Payment of exercise price or tax liability	$34,768 $5.51 p/Share	6,310 Reduced 3.92%	154,459 Common Stock
Feb 06 2023	BUY Grant, award, or other acquisition	-	45,500 Added 22.06%	160,769 Common Stock
Sep 01 2022	BUY Grant, award, or other acquisition	-	86,000 Added 42.73%	115,269 Common Stock
Feb 09 2021	BUY Conversion of derivative security	-	3,534 Added 10.77%	29,269 Common Stock

Also insider at

VYGR

Voyager Therapeutics, Inc. Healthcare

Chief Financial Officer

NDJ